Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Expression of p53 Breast Cancer in Kurdish Women in the West of Iran: a Reverse Correlation with Lymph Node Metastasis

  • Payandeh, Mehrdad (Department of Hematology and Medical Oncology, Kermanshah University of Medical Sciences) ;
  • Sadeghi, Masoud (Student Research Committee, Kermanshah University of Medical Sciences) ;
  • Sadeghi, Edris (Student Research Committee, Kermanshah University of Medical Sciences) ;
  • Madani, Seyed-Hamid (Medical Biology Research Center, Imam Reza Hospital, Kermanshah University of Medical Sciences)
  • Published : 2016.04.11
Download PDF
⟨ Previous Next ⟩

Abstract

Background: In breast cancer (BC), it has been suggested that nuclear overexpression of p53 protein might be an indicator of poor prognosis. The aim of the current study was to evaluate the expression of p53 BC in Kurdish women from the West of Iran and its correlation with other clinicopathology figures. Materials and Methods: In the present retrospective study, 231 patients were investigated for estrogen receptor (ER) and progesterone receptor (PR) positivity, defined as ${\geq}10%$ positive tumor cells with nuclear staining. A binary logistic regression model was selected using Akaike Information Criteria (AIC) in stepwise selection for determination of important factors. Results: ER, PR, the human epidermal growth factor receptor 2 (HER2) and p53 were positive in 58.4%, 55.4%, 59.7% and 45% of cases, respectively. Ki67 index was divided into two groups: 54.5% had Ki67<20% and 45.5% had Ki67 ${\geq}20%$. Of 214 patients, 137(64%) had lymph node metastasis and of 186 patients, 122(65.6%) had vascular invasion. Binary logistic regression analysis showed that there was inverse significant correlation between lymph node metastasis (P=0.008, OR 0.120 and 95%CI 0.025-0.574), ER status (P=0.006, OR 0.080, 95%CI 0.014-0.477) and a direct correlation between HER2 (P=005, OR 3.047, 95%CI 1.407-6.599) with the expression of p53. Conclusions: As in a number of studies, expression of p53 had a inverse correlation with lymph node metastasis and ER status and also a direct correlation with HER2 status. Also, p53-positivity is more likely in triple negative BC compared to other subtypes.

Keywords

References

  1. Aeinfar M, Najafi S, Payandeh M, Sadeghi M, Sadeghi E (2015). Clinicopathology figures of breast cancer women with brain metastasis and invasive ductal carcinoma. Am J Cancer Prev, 3, 68-71.
  2. Arun B, Kilic G, Yen C, et al (2003). Correlation of Bcl-2 and p53 expression in primary breast tumors and corresponding metastatic lymph nodes. Cancer, 98, 2554-9. https://doi.org/10.1002/cncr.11853
  3. Aylon Y, Oren M (2011). New plays in the p53 theater. Curr Opin Genet Dev, 21, 86-92. https://doi.org/10.1016/j.gde.2010.10.002
  4. Bertheau P, Steinberg SM, Merino MJ (1998). C-erbB-2, p53, and nm23 gene product expression in breast cancer in young women: immunohistochemical analysis and clinicopathologic correlation. Hum Pathol, 29, 323-9. https://doi.org/10.1016/S0046-8177(98)90111-3
  5. Carey LA, Perou CM, Livasy CA, et al (2006). Race, breast cancer subtypes, and survival in the Carolina Breast cancer Study. JAMA, 295, 2492-502. https://doi.org/10.1001/jama.295.21.2492
  6. De Azambuja E, Cardoso F, De Castro G, et al (2007). Ki67 as prognostic marker in early breast cancer: a meta-analysis of pub-lished studies involving 12.155 patients. Br J Cancer, 96, 1504-13. https://doi.org/10.1038/sj.bjc.6603756
  7. el-A Helal T, Khalifa A, Kamel AS (2000). Immunohistochemical expression of p53 and c-erbB2 proteins in breast cancer in Egypt. Anticancer Res, 20, 2145-50.
  8. Howard EM, Lau SK, Lyles RH, et al (2004). Correlation and expression of p53, HER-2, vascular endothelial growth factor (VEGF), and e-cadherin in a high-risk breast-cancer population. Int J Clin Oncol, 9, 154-60.
  9. Jasar Dz, Smichkoska S, Kubelka K, Filipovski V, Petrushevska G (2015). Expression of p53 protein product in triple negative breast cancers and relation with clinical and histopathological parameters. Prilozi, 36, 69-79. https://doi.org/10.1515/prilozi-2015-0031
  10. Lacroix M, Toillon RA, Leclercq G (2006). p53 and breast cancer, an update. Endocr Relat Cancer, 13, 293-325. https://doi.org/10.1677/erc.1.01172
  11. Li X, Wang Q, Fu L, Liu M, Yu X (2015). Expression of PTEN, p53 and EGFR in the molecular subtypes of breast carcinoma and the correlation among them. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 40, 973-8 (in Chinese).
  12. Osanai T, Takagi Y, Toriya Y, et al (2005). Inverse correlation between the expression of O6-methylguanine-DNA methyl transferase (MGMT) and p53 in breast cancer. Jpn J Clin Oncol, 35, 121-5. https://doi.org/10.1093/jjco/hyi036
  13. Payandeh M, Malayeri R, Sadeghi M, Sadeghi E, Gholami, F (2015c). Expression of p53 and Ki67 in the patients with triple negative breast cancer and invasive ductal carcinoma. Am J Cancer Prev, 3, 58-61.
  14. Payandeh M, Sadeghi M, Sadeghi E, Aeinfar M (2015a). Clinicopathology figures and long-term effects of tamoxifen plus radiation on survival of women with invasive ductal carcinoma and triple negative breast cancer. Asian Pac J Cancer Prev, 16, 4863-7. https://doi.org/10.7314/APJCP.2015.16.12.4863
  15. Payandeh M, Sadeghi M, Sadeghi E (2015b). Differences in prognostic factors between early and late recurrence breast cancers. Asian Pac J Cancer Prev, 16, 6575-9. https://doi.org/10.7314/APJCP.2015.16.15.6575
  16. Pharoah PD, Day NE, Caldas C (1999). Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer, 80, 1968-73. https://doi.org/10.1038/sj.bjc.6690628
  17. Qing Z, Zou W, Luo J, Wen Q, Fan S (2014). [p53 protein expression in HER2-negative breast invasive ductal carcinoma]. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 39, 1016-22.
  18. Rakha EA, El-Sayed ME, Green AR, et al (2007). Prognostic markers in triple negative breast cancer. Cancer, 109, 25-32. https://doi.org/10.1002/cncr.22381
  19. Shapochka DO, Zaletok SP, Gnidyuk MI (2012). Relationship between NF-${\kappa}B$, ER, PR, Her2/neu, Ki67, p53 expression in human breast cancer. Exp Oncol, 34, 358-63.
  20. Sirvent JJ, Salvado MT, Santafe M, et al (1995). p53 in breast cancer. Its relation to histological grade, lymph-node status, hormone receptors, cell-proliferation fraction (ki-67) and c-erbB-2. Immunohistochemical study of 153 cases. Histol Histopathol, 10, 531-9.
  21. Sjostrom-Mattson J, Von Boguslawski K, Bengtsson NO, et al (2009). The expression of p53, bcl-2, bax, fas and fasL in the primary tumour and lymph node metastases of breast cancer. Acta Oncol, 48, 1137-43. https://doi.org/10.3109/02841860902988688
  22. Temmim L, Baker H, Sinowatz F (2001). Immunohistochemical detection of p53 protein expression in breast cancer in young Kuwaiti women. Anticancer Res, 21, 743-8.
  23. Vernet-Tomas M, Banos N, Sabadell D, et al (2015). p53 expression in breast cancer predicts tumors with low probability of non-sentinel nodes infiltration. J Obstet Gynaecol Res, 41, 1115-21. https://doi.org/10.1111/jog.12670
  24. Voduc KD, Cheang MC, Tyldesley S, et al (2010). Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol, 28, 1684-91. https://doi.org/10.1200/JCO.2009.24.9284
  25. Wang XZ, Liu Q, Sun JJ, et al (2015). Correlation between p53 and epidermal growth factor receptor expression in breast cancer classification. Genet Mol Res, 14, 4282-90. https://doi.org/10.4238/2015.April.28.10

Cited by

  1. Comparative study of Her-2, p53, Ki-67 expression and clinicopathological characteristics of breast cancer in a cohort of northern China female patients vol.8, pp.4, 2017, https://doi.org/10.1080/21655979.2016.1235101